Amgen Drug Succeeds in Late-Stage Sjögren’s Disease Trial

Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.